WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs
Executive Summary
The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia
You may also be interested in...
Biologic “Functional Equivalence” Being Considered By Insurers – WellPoint
Managed care plans increasingly are moving toward selecting preferred biologic agents within a therapeutic class, WellPoint VP & Chief Pharmacy Officer Robert Seidman said
Biologic “Functional Equivalence” Being Considered By Insurers – WellPoint
Managed care plans increasingly are moving toward selecting preferred biologic agents within a therapeutic class, WellPoint VP & Chief Pharmacy Officer Robert Seidman said
Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition
WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines